.webp)
The global acetylcysteine industry is anticipated experience remarkable growth between 2022 and 2027, led by robust demand across key application segments. The product finds wide use across medicine, nutritional supplements, dietary supplements, and several other key applications. Commonly known as N-acetylcysteine (NAC), it is basically a modified amino acid that serves as an antidote to prevent liver damage from paracetamol (acetaminophen) overdose.
Acetylcysteine is also utilized to treat chronic respiratory conditions such as bronchitis and pneumonia. It helps in thinning the thick mucus in individuals suffering from these diseases to clear out the airways.
Business Research Insights forecasts the global market for acetylcysteine to hit USD 3,522.7 million by 2027 at a CAGR of 21.5% during 2022-2027. Expanding applications across pharmaceutical and dietary supplements will drive the growth of the market.
COVID-19 Accelerated R&D Around Potential Benefits of Acetylcysteine
Acetylcysteine is a supplement of cysteine that is commonly found in foods such as chicken, eggs, turkey, yogurt, legumes, and seeds. Owing to its anti-coagulative, anti-oxidative, and anti-inflammatory properties, the substance gained significant interest from the scientific and research community as a medication that could potentially prevent COVID-19. Consequently, increasing R&D to further assess the potential benefits of the substance in preventing coronavirus infections as well as other respiratory diseases will create a favorable outlook for the industry over the next few years.
Business Research Insights Presents the Top 5 Acetylcysteine Manufacturing Companies Globally
1. Zambon (Italy)
Italy-based Zambon has been operating in the pharmaceutical and fine chemical sector since 1906. The company has business operations across three continents, Europe, Asia, and South America. Zambon employs more than 2,600 people across 15 countries.
In July 2019, Zambon completed the acquisition of Breath Therapeutics to boost development of solutions for bronchiolitis obliterans syndrome, an uncommon respiratory disease.
2. Nippon Rika (Japan)
Headquartered in Tokyo, Japan, Nippon Rika is one of the world’s leading manufacturers of non-metallic mineral products. Based on robust synthesis technology and high-quality assurance, the company is one of the world’s leading producers of bulk pharmaceutical chemicals complying with the Good Manufacturing Practice (GMP) regulations of Japan, the EU, and the U.S. Nippon Rika has approval for the production of bulk pharmaceutical products from the U.S. Food and Drug Administration (FDA) and the Japanese Ministry of Health, Labor, and Welfare (MHLW).
3. PharmaZell (India)
PharmaZell provides a rich portfolio of small molecule Active Pharmaceutical Ingredients (APIs) along with custom manufacturing and development services for the originator and generic pharmaceutical sector. The company operates with about 750 employees across three major production sites, two in India and one in Germany.
In September 2021, PharmaZell announced a merger with Novasep to expand SPI and CDMO service offerings.
4. Moehs (Spain)
Moehs Group represents a dynamic group of companies in the pharmaceutical ingredients business. The company manufactures and sells more than 75 products in around 90 countries across the world. Moehs has seven manufacturing units worldwide that are highly flexible due to being multipurpose plants. The company has a number of research & development centers for the synthesis of APIs.
5. Wuhan Grand Hoyo (China)
Wuhan Grand Hoyo Company Ltd. is a Chinese company specializing in the research, synthesis, development, and commercialization of amino acids and related derivatives. The company provides its products and services to customers across China. Wuhan Grand Hoyo also specializes in the production of APIs. Amino acids and derivatives produced by the company are used in food/feed additives, pharmaceuticals, nutritional supplements, and other applications. The company has CEP certification for acetylcysteine.
Pharmaceutical and Nutritional Supplements will Continue to Generate Robust Demand
The continuous uptick in the occurrence of several chronic diseases and increasing healthcare R&D mean that the pharmaceutical sector will continue to present new opportunities for product suppliers. Meanwhile, nutritional supplements are experiencing significant demand across various consumer segments. Growing popularity of supplements will certainly propel the market for acetylcysteine in the next several years.